These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 17097375)

  • 1. Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.
    Hofmann SC; Technau K; Müller AM; Lübbert M; Bruckner-Tuderman L
    J Am Acad Dermatol; 2007 May; 56(5 Suppl):S68-72. PubMed ID: 17097375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition].
    Moles MP; Landry J; Roche-Lestienne C; Godon A; Schmidt-Tanguy A; Gardembas M; Le Clech C; Verret JL; Zandecki M; Blanchet O
    Ann Biol Clin (Paris); 2005; 63(3):317-22. PubMed ID: 15951264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imatinib mesylate for the treatment of hypereosinophilic syndromes.
    Antoniu SA
    Curr Opin Investig Drugs; 2006 Nov; 7(11):980-4. PubMed ID: 17117585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of idiopathic hypereosinophilic syndrome with imatinib].
    Sørensen AL; Larsen H
    Ugeskr Laeger; 2008 Jan; 170(4):254. PubMed ID: 18282461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.
    Garg A; Duggal L; Aggarwal S; Jain N
    J Assoc Physicians India; 2006 Nov; 54():883-6. PubMed ID: 17249259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term remission of lymphocytic hypereosinophilic syndrome with imatinib mesylate.
    Christoforidou A; Kotsianidis I; Margaritis D; Anastasiadis A; Douvali E; Tsatalas C
    Am J Hematol; 2012 Jan; 87(1):131-2. PubMed ID: 21919038
    [No Abstract]   [Full Text] [Related]  

  • 7. [Idiopathic hypereosinophilic syndrome and bullous pemphigoid].
    Belgnaoui F; Idrissi M; Benyoussef K; Loudiye T; Bella A; Senouci K; Aouni M; Mansouri F; Heid E; Hassam B
    Ann Dermatol Venereol; 2002 Nov; 129(11):1291-4. PubMed ID: 12514518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.
    Payne SM; Kovacs MJ
    Ann Pharmacother; 2004; 38(7-8):1215-8. PubMed ID: 15187212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone.
    Wang JR; Yen CC; Gau JP; Hsiao LT; Liu CY; Pai JT; Tzeng CH; Teng HW
    J Clin Pharm Ther; 2010 Dec; 35(6):733-6. PubMed ID: 21054467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soft tissue and skeletal involvement in FIP1L1-PDGFR-alpha positive chronic eosinophilic leukemia: imatinib mesylate may induce complete molecular and imaging remission.
    Malagola M; Martinelli G; Rondoni M; Ottaviani E; Piccaluga PP; Ricci P; Visani G; Baccarani M
    Haematologica; 2004 Aug; 89(8):ECR25. PubMed ID: 15339694
    [No Abstract]   [Full Text] [Related]  

  • 11. Hypereosinophilic syndrome: diagnosis and treatment.
    Peros-Golubicić T; Smojver-Jezek S
    Curr Opin Pulm Med; 2007 Sep; 13(5):422-7. PubMed ID: 17940488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.
    Lierman E; Cools J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1295-304. PubMed ID: 19761433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis.
    Ishii Y; Ito Y; Kuriyama Y; Tauchi T; Ohyashiki K
    Leuk Res; 2004 May; 28 Suppl 1():S79-80. PubMed ID: 15036947
    [No Abstract]   [Full Text] [Related]  

  • 14. Imatinib-mesylate for all patients with hypereosinophilic syndrome?
    Musto P; Perla G; Minervini MM; Carella AM; Coco FL; Catalano G
    Leuk Res; 2004 Jul; 28(7):773-4. PubMed ID: 15158099
    [No Abstract]   [Full Text] [Related]  

  • 15. [A man with FIP1L1/PDGFRA-positive chronic eosinophilic leukemia].
    Leeksma OC; de Ruiter GS; van der Hulst VP; Terpstra WE; Cools J; Vandenberghe P
    Ned Tijdschr Geneeskd; 2006 Sep; 150(35):1936-43. PubMed ID: 16999279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hypereosinophilic syndromes: still more heterogeneity.
    Gleich GJ; Leiferman KM
    Curr Opin Immunol; 2005 Dec; 17(6):679-84. PubMed ID: 16214314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent cough: an unusual cause. Idiopathic hypereosinophilic syndrome (HES).
    Barker B; Moudgil H; Slocombe G; Srinivasan K
    Thorax; 2010 Nov; 65(11):1009, 1024. PubMed ID: 20965936
    [No Abstract]   [Full Text] [Related]  

  • 18. Imatinib: new indication. New indications, but not robust evidence.
    Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis.
    Musto P; Falcone A; Sanpaolo G; Bodenizza C; Perla G; Minervini MM; Cascavilla N; Dell'Olio M; La Sala A; Mantuano S; Melillo L; Nobile M; Scalzulli PR; Bisceglia M; Carella AM
    Leuk Lymphoma; 2004 Jun; 45(6):1219-22. PubMed ID: 15360005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
    Schaller JL; Burkland GA
    MedGenMed; 2001 Sep; 3(5):9. PubMed ID: 11698916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.